Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: An Individual Patient Data Meta-Analysis Using Propensity Matching
James Trauer, Stephen Muhi, Emma S McBryde, Shmeylan A Al Harbi, Yaseen M Arabi, Andrew J Boyle, Rodrigo Cartin-Ceba, Wei Chen, Yung-Tai Chen, Marco Falcone, Ognjen Gajic, Jack Godsell, Michelle Ng Gong, Daryl Kor, Wolfgang Loesche, Daniel F McAuley, Hollis R O'Neal, Michael Osthoff, Gordon P Otto, Maik Sossdorf Show all
Critical Care Medicine | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017
Drs. Gong, Kor, O'Neal, and Ware received support for article research from the National Institutes of Health (NIH). Dr. Gong's institution received funding from the National Heart, Lung, and Blood Institute. Dr. Kor's institution received funding from the NIH, and he disclosed off-label product use of aspirin. Dr. McAuley received funding from Peptinnovate, Bayer, GlaxoSmithKline, Boehringer Ingelheim (consulting). Outside the submitted work, his institution has received funds from grants from the U.K. National Institute for Health Research and others, and he is one of the four named inventors on a patent US8962032 covering the use of sialic acid-bearing nanoparticles as anti-inflammatory agents issued to his institution, The Queen's University of Belfast (http://www.google.com/patents/US8962032). Dr. Osthoff's institution received funding from Pharming Technologies B.V. Dr. Ware's institution received funding from the NIH, Boehringer Ingelheim, and Global Blood Therapeutics. Dr. Winning disclosed off-label product use of aspirin. The remaining authors have disclosed that they do not have any potential conflicts of interest.